- Home
- CSTL vs AVK Comparison
CSTL vs AVK Comparison
Compare CSTL & AVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- AVK
- Stock Information
- Founded
- CSTL 2007
- AVK 2003
- Country
- CSTL United States
- AVK United States
- Employees
- CSTL N/A
- AVK N/A
- Industry
- CSTL Medical Specialities
- AVK Trusts Except Educational Religious and Charitable
- Sector
- CSTL Health Care
- AVK Finance
- Exchange
- CSTL Nasdaq
- AVK Nasdaq
- Market Cap
- CSTL 456.2M
- AVK 523.6M
- IPO Year
- CSTL 2019
- AVK N/A
- Fundamental
- Price
- CSTL $20.49
- AVK $12.15
- Analyst Decision
- CSTL Strong Buy
- AVK
- Analyst Count
- CSTL 6
- AVK 0
- Target Price
- CSTL $37.67
- AVK N/A
- AVG Volume (30 Days)
- CSTL 449.7K
- AVK 112.9K
- Earning Date
- CSTL 08-04-2025
- AVK 01-01-0001
- Dividend Yield
- CSTL N/A
- AVK 11.85%
- EPS Growth
- CSTL N/A
- AVK N/A
- EPS
- CSTL N/A
- AVK N/A
- Revenue
- CSTL $347,083,000.00
- AVK N/A
- Revenue This Year
- CSTL N/A
- AVK N/A
- Revenue Next Year
- CSTL $1.36
- AVK N/A
- P/E Ratio
- CSTL N/A
- AVK N/A
- Revenue Growth
- CSTL 38.43
- AVK N/A
- 52 Week Low
- CSTL $15.45
- AVK $9.24
- 52 Week High
- CSTL $35.84
- AVK $12.16
- Technical
- Relative Strength Index (RSI)
- CSTL 67.41
- AVK 67.45
- Support Level
- CSTL $18.18
- AVK $11.56
- Resistance Level
- CSTL $20.63
- AVK $12.16
- Average True Range (ATR)
- CSTL 0.78
- AVK 0.13
- MACD
- CSTL 0.22
- AVK 0.02
- Stochastic Oscillator
- CSTL 85.79
- AVK 91.67
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.